The Concept of “Silent Cardiovascular Risk”: What Most People Miss

1. Introduction: The Limits of Symptom-Based Risk Detection

Cardiovascular disease (CVD) remains the leading cause of premature mortality globally, responsible for an estimated 17.9 million deaths per year. What is perhaps less widely appreciated is how frequently the first clinical manifestation of cardiovascular disease is also its most catastrophic: approximately half of all myocardial infarctions and a substantial proportion of strokes occur in individuals with no prior cardiac symptoms and no established CVD diagnosis. They were not, in any meaningful clinical sense, asymptomatic - they were unassessed.

This is the central paradox of cardiovascular risk in contemporary medicine. The tools most widely used to stratify risk - Framingham, SCORE2, QRISK3 - are population-derived algorithms calibrated to identify individuals at elevated average risk based on traditional risk factors: age, sex, smoking status, cholesterol, and blood pressure. They are valuable instruments, but they are not designed to detect the subclinical vascular damage that accumulates silently in individual patients over years or decades before producing a clinical event. A patient can carry a ten-year cardiovascular risk of 7% on SCORE2 - classified as moderate - while simultaneously harbouring asymptomatic left ventricular hypertrophy, masked nocturnal hypertension, and microalbuminuria, each of which independently and materially elevates their true event risk.

The concept of silent cardiovascular risk describes exactly this gap: the burden of subclinical vascular injury, haemodynamic dysfunction, and early target organ damage that exists below the threshold of symptoms and outside the reach of standard risk calculators. It is not a theoretical construct. Each of its constituent entities is measurable, clinically validated, and actionable. The challenge for the practitioner is knowing where to look, in whom, and with which tools.

This article maps the clinical landscape of silent cardiovascular risk, identifies the patient profiles most likely to carry undetected burden, and provides practical guidance on the investigative strategies most suited to surfacing it in routine practice.

2. What Silent Cardiovascular Risk Looks Like: Key Clinical Entities

Silent cardiovascular risk is not a single condition but a cluster of distinct, often co-occurring clinical entities, each with its own pathophysiology, prevalence, and clinical significance. What they share is a common characteristic: they are routinely missed because they produce no symptoms and are not captured by standard office-based assessment.

Undetected and Masked Hypertension

Hypertension affects approximately 1.28 billion adults worldwide, yet an estimated 46% of those with hypertension are unaware of their diagnosis. Undetected hypertension - most commonly identified incidentally or through opportunistic screening - represents the largest single component of preventable cardiovascular burden in the general population.

Masked hypertension is a distinct and more insidious phenomenon: office BP readings appear normal, but out-of-office BP - measured by ambulatory monitoring (ABPM) or home BP monitoring (HBPM) - reveals sustained elevation. Prevalence estimates range from 10 to 30% of the general hypertensive population, and masked hypertension is associated with cardiovascular event risk comparable to sustained hypertension - significantly higher than in true normotensives. It is, by definition, invisible to any clinical assessment strategy that relies exclusively on office measurement. Patients with borderline office BP readings, those with high cardiovascular risk profiles despite normal clinic BP, and those with unexplained target organ damage are the highest-yield group for ABPM-based screening.

Nocturnal Hypertension and Non-Dipping

Under normal physiological conditions, blood pressure falls by 10–20% during sleep - the nocturnal dip - reflecting reduced sympathetic tone and cardiac output during rest. Failure to achieve this dip (non-dipping, defined as a nocturnal reduction of less than 10%) or reversal of the pattern (reverse dipping, where nocturnal BP exceeds daytime BP) is associated with substantially increased risk of stroke, coronary events, and renal disease, independent of mean 24-hour BP.

Nocturnal hypertension and non-dipping are almost entirely invisible to office-based assessment and are identified only through ABPM or HBPM. Their prevalence is high: non-dipping is estimated to affect 25–35% of hypertensive patients, and is more common in patients with diabetes, chronic kidney disease, obstructive sleep apnoea, and autonomic dysfunction. Because these are precisely the patients whose cardiovascular risk is already elevated, failure to identify nocturnal BP patterns in this group represents a clinically significant missed opportunity for risk reclassification and management optimisation.

OMRON Healthcare offers a device called NightView, a wrist blood pressure monitor specifically designed for home monitoring of nighttime blood pressure. It automatically takes measurements while the patient is asleep, helping to detect nocturnal hypertension that standard daytime measurements often miss. In fact, night-time BP has been shown to be a stronger predictor of cardiovascular risk than daytime BP.

Blood Pressure Variability

Visit-to-visit blood pressure variability - the fluctuation in BP readings across clinical encounters - is an independent predictor of stroke, myocardial infarction, and cardiovascular mortality, over and above mean BP. A patient whose systolic BP varies between 118 and 158 mmHg across five clinic visits carries materially higher vascular risk than a patient with a stable mean of 138 mmHg, even though their average readings may be identical.

BPV is routinely missed in clinical practice for a straightforward reason: most clinical records do not aggregate serial BP readings in a format that enables variability to be assessed. A single reading at each visit, recorded in a free-text field, provides no basis for calculating standard deviation or coefficient of variation across encounters. Practices that record BP numerically and systematically across visits - or that use validated home monitoring data reviewed longitudinally - are better positioned to detect high-variability patients who may be clinically underrecognised as high risk.

Silent Myocardial Ischaemia

Silent myocardial ischaemia - objective evidence of myocardial ischaemia in the absence of anginal symptoms - is estimated to account for 70–80% of all ischaemic episodes in patients with known coronary artery disease. Its prevalence in the general population of patients with cardiovascular risk factors but without established coronary disease is less precisely characterised, but studies using exercise testing and ambulatory ECG monitoring have identified silent ischaemia in 2–10% of asymptomatic middle-aged adults with diabetes or hypertension.

The clinical significance is not trivial: silent ischaemia is associated with increased risk of subsequent myocardial infarction, sudden cardiac death, and arrhythmia. It is most commonly missed because the absence of chest pain removes the clinical trigger for investigation. In patients with multiple cardiovascular risk factors - particularly diabetes, in which autonomic neuropathy impairs pain perception - a lower threshold for functional cardiac assessment is warranted.

Asymptomatic Left Ventricular Hypertrophy

Left ventricular hypertrophy (LVH) is the structural cardiac response to sustained pressure overload, most commonly driven by hypertension. It is present in approximately 15–20% of hypertensive adults in the general population, rising to 30–40% in those with poorly controlled or long-standing hypertension. LVH is a powerful independent predictor of cardiovascular events: its presence reclassifies patients into a higher-risk category and is explicitly recognised as a target organ damage marker in the 2023 ESH / 2024 ESC hypertension guidelines, where it modifies risk management recommendations.

Despite its prognostic significance, LVH is asymptomatic until it contributes to heart failure, arrhythmia, or ischaemia. ECG has limited sensitivity for LVH detection (approximately 50–60% in hypertensive populations); echocardiography is the reference standard and is considerably more sensitive. The majority of hypertensive patients in primary care have never had an echocardiogram, meaning that a substantial proportion of LVH in the community remains undetected and unaccounted for in risk stratification.

Microalbuminuria

Microalbuminuria - a urine albumin-to-creatinine ratio (ACR) of 3–30 mg/mmol - is an early marker of glomerular endothelial dysfunction and renal microvascular injury. It is also a systemic marker: its presence reflects endothelial damage extending beyond the kidney, and it is independently associated with increased cardiovascular event risk in both diabetic and non-diabetic populations. The 2023 ESH / 2024 ESC guidelines classify microalbuminuria as a subclinical target organ damage marker that should prompt upward risk reclassification.

Microalbuminuria is detected by a simple urine dipstick or laboratory ACR measurement - a low-cost, non-invasive test that is routinely performed in diabetic patients but frequently omitted in hypertensive patients without diabetes. Given its prevalence (estimated at 5–10% of the general adult hypertensive population) and its independent prognostic value, ACR measurement deserves broader integration into routine cardiovascular risk assessment.

3. Who Is Most Likely to Carry Undetected Risk?

Silent cardiovascular risk is not uniformly distributed. Certain patient profiles are disproportionately likely to harbour subclinical burden that standard assessment strategies will miss. Identifying these patients enables more targeted deployment of the investigative tools discussed in Section 4.

Middle-Aged Adults with Borderline Risk Scores

Risk calculators are most discriminating at the extremes of the risk distribution: they reliably identify the genuinely low-risk and the clearly high-risk patient. It is the patient in the intermediate zone - a ten-year cardiovascular risk of 5–10% on SCORE2, classified as moderate - where the greatest diagnostic uncertainty lies and where subclinical markers have the highest potential to reclassify management.

A 52-year-old man with borderline hypertension, a mildly elevated LDL, and no smoking history may score as moderate risk. The same patient with echocardiographically confirmed LVH, an ACR of 8 mg/mmol, and a masked nocturnal hypertension pattern on ABPM is, by ESC criteria, high risk. The risk calculator could not have told the clinician this. Systematic screening for subclinical markers in borderline-risk patients is therefore where clinical judgement adds the greatest marginal value over algorithmic risk scoring.

Patients with White-Coat Normotension

White-coat normotension - where office BP is normal but the patient’s true out-of-office BP is elevated - is the inverse of white-coat hypertension and represents the principal mechanism by which masked hypertension arises. It is most common in patients who are physiologically reactive to the clinical encounter, including younger adults, those with anxiety, and those with a strong family history of hypertension who are particularly alert to BP measurement.

These patients are clinically invisible without out-of-office monitoring. Their normal office BP generates appropriate clinical reassurance; their cardiovascular risk is managed as if they were normotensive; and their actual haemodynamic profile - which may include sustained daytime elevation or nocturnal hypertension - goes undetected. A high index of suspicion is warranted in patients whose family history, metabolic profile, or early target organ findings are inconsistent with their apparently normal office BP.

Shift Workers and Those with Disrupted Sleep

Circadian disruption - arising from rotating shift work, night work, severe insomnia, or obstructive sleep apnoea - is an underappreciated driver of nocturnal hypertension and non-dipping. The nocturnal BP dip is a circadian phenomenon, dependent on the sustained reduction in sympathetic tone that accompanies normal sleep. When sleep architecture is fragmented or the sleep-wake cycle is chronically misaligned, this dip is attenuated or abolished.

Shift workers represent approximately 20% of the working population in developed economies and carry an elevated risk of cardiovascular events that is not fully accounted for by traditional risk factors. Office-based BP measurement in shift workers is further confounded by the fact that their working hours may mean that clinic appointments systematically occur at atypical points in their circadian cycle, making office readings particularly unreliable. ABPM, conducted across a typical 24-hour period including their work pattern, is the most clinically informative assessment for this group.

Patients with Metabolic Syndrome

Metabolic syndrome - the cluster of central obesity, dyslipidaemia, impaired fasting glucose, and hypertension - is associated with a substantially elevated prevalence of each of the silent risk entities described in Section 2. Insulin resistance drives RAAS activation, sympathetic hyperactivity, and sodium retention, all of which contribute to masked and nocturnal hypertension. Visceral adiposity is independently associated with LVH and microalbuminuria. And the inflammatory and endothelial milieu of metabolic syndrome accelerates subclinical atherosclerosis, increasing the likelihood of silent myocardial ischaemia.

Patients with metabolic syndrome who score as moderate risk on standard calculators are a high-priority group for subclinical screening: their standard risk score systematically underestimates their true vascular burden, and the yield of targeted investigation in this group is correspondingly high.

Higher-Risk Demographic Groups

Several demographic groups carry elevated silent cardiovascular risk that is not fully captured by standard risk calculators:

• Patients of South Asian ethnicity: Higher prevalence of insulin resistance and metabolic syndrome at lower BMI thresholds, with correspondingly elevated rates of subclinical cardiovascular disease relative to standard risk predictions.

• Patients of African or Afro-Caribbean descent: Higher prevalence of hypertension, greater tendency toward salt-sensitive and volume-dependent BP patterns, and higher rates of hypertensive target organ damage including LVH and renal disease.

• Women with a history of hypertensive pregnancy disorders: Pre-eclampsia and gestational hypertension are associated with a two- to fourfold increase in long-term cardiovascular risk, including masked hypertension and accelerated subclinical atherosclerosis, that persists decades after delivery and is frequently underrecognised in routine practice.

• Patients with severe mental illness: Antipsychotic medications, metabolic dysregulation, and lifestyle factors combine to produce a cardiovascular risk burden substantially higher than standard calculators predict, with high rates of silent ischaemia and undetected hypertension.

4. Investigative Tools for Detecting Silent Risk in Practice

Each component of silent cardiovascular risk has a corresponding investigative tool. The challenge for the clinician is deploying these tools judiciously - targeting higher-yield patients rather than applying a universal screening battery - and interpreting the results within a broader risk stratification framework.

Ambulatory BP Monitoring and Home BP Monitoring

ABPM is the reference standard for detecting masked hypertension, nocturnal hypertension, and non-dipping patterns. It should be considered in:

• Patients with borderline office BP (systolic 130–139 mmHg) and elevated cardiovascular risk

• Patients with office BP apparently well-controlled but unexplained target organ damage

• Shift workers and patients with disrupted sleep or suspected OSA

• Patients with a strong family history of premature cardiovascular disease and normal office BP

• Any patient in whom masked hypertension is clinically suspected

HBPM provides a practical complement to ABPM for longitudinal surveillance. A standardised seven-day protocol (duplicate morning and evening readings, first day discarded) generates a reliable mean and, when repeated across visits, enables visit-to-visit variability to be assessed. Clinicians should verify that patients use validated devices (STRIDE BP registry) and adhere to a consistent measurement protocol.

ECG and Echocardiography for LVH

A resting 12-lead ECG should be performed in all hypertensive patients as part of the initial cardiovascular assessment and repeated if clinical status changes. ECG criteria for LVH (Sokolow-Lyon, Cornell voltage) have moderate sensitivity (approximately 50–60%) but high specificity and require no additional resource beyond a standard ECG machine.

Echocardiography is the reference standard for LVH assessment and provides substantially greater sensitivity, as well as information on diastolic function, wall motion, and valvular pathology. It is indicated in hypertensive patients with ECG evidence of LVH, those with unexplained breathlessness or exercise intolerance, those with a high cardiovascular risk profile, and those in whom risk reclassification based on LVH status would change management intensity. In resource-constrained settings, prioritisation should focus on patients with borderline risk scores and those with the metabolic profiles associated with highest LVH prevalence.

Urine ACR for Microalbuminuria

Urine albumin-to-creatinine ratio (ACR) measurement requires a single spot urine sample and is available in most primary care and outpatient settings. It should be performed at initial cardiovascular risk assessment in all hypertensive patients, and annually thereafter in those with diabetes, CKD, or established cardiovascular disease. An ACR of 3–30 mg/mmol on two out of three samples confirms microalbuminuria; ACR above 30 mg/mmol indicates macroalbuminuria and warrants nephrology review.

A positive result should prompt upward risk reclassification in accordance with ESC/ESH guidance, review of BP control (given that persistent microalbuminuria reflects inadequate haemodynamic protection of the renal microvasculature), and assessment of other subclinical markers.

Resting and Exercise ECG for Silent Ischaemia

Silent myocardial ischaemia is most commonly detected through resting ECG (ST-segment changes, Q waves, bundle branch block), exercise stress testing (ST depression with exertion in the absence of symptoms), or ambulatory ECG monitoring. In patients with multiple cardiovascular risk factors - particularly those with diabetes, in whom autonomic neuropathy blunts anginal symptoms - a lower threshold for functional cardiac assessment is clinically justified.

The ESC 2021 CVD prevention guidelines do not recommend universal screening for silent ischaemia in asymptomatic populations, but support targeted investigation in high-risk individuals where detection would change management. Clinicians should apply this framework to the patient profiles described in Section 3 rather than as a blanket population screening strategy.

5. Translating Silent Risk into Clinical Action

Detection of subclinical cardiovascular markers has clinical value only if it is systematically translated into management decisions. The ESC 2021 cardiovascular disease prevention guidelines and the 2023 ESH / 2024 ESC hypertension guidelines provide an explicit framework for this translation, centred on the concept of risk modifier reclassification.

Risk Reclassification Based on Subclinical Markers

The 2023 ESH / 2024 ESC guidelines identify the following subclinical target organ damage markers as risk modifiers that can upwardly reclassify a patient from one risk category to the next:

• LVH on ECG or echocardiography

• Microalbuminuria (ACR 3–30 mg/mmol) or reduced eGFR

• Increased carotid intima-media thickness or carotid plaque on ultrasound

• Increased arterial stiffness (pulse wave velocity >10 m/s)

• Ankle-brachial index below 0.9

The clinical implication is direct: a patient classified as moderate risk on SCORE2 who is found to have LVH and microalbuminuria should be reclassified as high risk, with corresponding implications for BP treatment targets, statin indication thresholds, and monitoring intensity. This reclassification is not discretionary - it is the intended clinical application of subclinical marker data within the ESC risk stratification framework.

Masked and Nocturnal Hypertension: Management Implications

Detection of masked hypertension or significant nocturnal hypertension through ABPM should prompt treatment review even when office BP appears well-controlled. The 2023 ESH / 2024 ESC guidelines specify that the treatment target for masked hypertension is equivalent to that for sustained hypertension, and that nocturnal BP should be considered alongside daytime BP when assessing overall haemodynamic burden. For antihypertensive selection and dosing strategy in the context of nocturnal hypertension, clinicians are referred to current ESC/ESH guidance.

Blood Pressure Variability: Implications for Monitoring Strategy

High visit-to-visit BP variability, once identified, should prompt a review of monitoring frequency and strategy rather than an immediate change in pharmacological management. Increasing the density of BP readings - through structured HBPM or more frequent clinic measurement - allows the clinician to distinguish true haemodynamic instability from measurement artefact, to characterise the pattern of variability (morning surge, post-dose troughs, diurnal fluctuation), and to inform any subsequent management adjustments within the framework of current guidelines.

Integrating Findings into a Unified Risk Assessment

The most clinically effective approach to silent cardiovascular risk is not to investigate each entity in isolation, but to integrate findings across markers into a unified reassessment of the patient’s overall risk profile. A patient found to have masked nocturnal hypertension, microalbuminuria, and borderline LVH on ECG is not three patients with three separate findings - they are a single patient whose subclinical burden, taken together, substantially exceeds what their standard risk score would suggest. Documenting this integrated picture explicitly, and using it to drive management intensity decisions, is the clinical translation that converts silent risk detection into patient benefit.

6. Conclusion

Silent cardiovascular risk is not a marginal clinical curiosity - it is the primary mechanism by which cardiovascular disease presents without warning in a substantial proportion of affected individuals. The tools to detect it are available, validated, and in most cases accessible within routine practice. What is required is a systematic clinical intention to look beyond symptom status and standard risk scores in the patients most likely to harbour undetected subclinical burden.

Key practice points for clinicians:

• Do not equate absence of symptoms with absence of cardiovascular risk. The majority of ischaemic episodes, a substantial proportion of hypertensive target organ damage, and a significant share of stroke risk arise in patients who feel entirely well.

• Treat standard risk calculators as a starting point, not an endpoint. In patients with borderline risk scores, metabolic syndrome, white-coat normotension, or demographic profiles associated with elevated silent risk, targeted subclinical screening is clinically justified and guideline-supported.

• Deploy ABPM systematically in patients where masked hypertension, nocturnal hypertension, or high BP variability is clinically suspected. Home BP monitoring provides a complementary longitudinal dataset that clinic encounters cannot replicate.

• Integrate ACR measurement into routine cardiovascular risk assessment for all hypertensive patients, not only those with diabetes. Its low cost, non-invasive nature, and independent prognostic value make it among the highest-yield additions to standard assessment.

• Use subclinical marker findings to drive formal risk reclassification in accordance with ESC/ESH guidance, and document the basis for any upward reclassification explicitly in the clinical record.

Among the investigative tools available for detecting silent cardiovascular risk, structured out-of-office blood pressure monitoring - through ABPM and validated home monitoring - offers the most accessible, scalable, and clinically actionable route to surfacing the haemodynamic patterns that clinic-based assessment consistently misses. Longitudinal home BP data reviewed systematically at each clinical encounter is not merely a monitoring convenience: it is a risk detection strategy for the patients most likely to present without warning.

Omron Healthcare offers a range of clinically validated home blood pressure monitors designed to support structured out-of-office monitoring, enabling practitioners to build the longitudinal haemodynamic datasets that silent cardiovascular risk detection requires.

Approval Code: OHEAPP-1176